videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Herantis Pharma

Herantis Pharma valmistautuu seuraavaan vaiheeseen. Tuore toimitusjohtaja Craig Cook kommentoi Vernerin haastattelussa yhtiön kehitysvaihetta ja mitä seuraava vaihe tarkoittaa sijoittajan kannalta.

Herantis Pharma valmistautuu seuraavaan vaiheeseen. Tuore toimitusjohtaja Craig Cook kommentoi Vernerin haastattelussa yhtiön kehitysvaihetta ja mitä seuraava vaihe tarkoittaa sijoittajan kannalta. Haastattelu on englanniksi. Aiheet kellotettuna alla. Herantis Pharmasta kirjoitetaan Sijoitusfoorumilla <a href="https://keskustelut.inderes.fi/t/herantis-pharma-ketju/">https://keskustelut.inderes.fi/t/herantis-pharma-ketju/</a> 00:00 Intro 00:06 Craig, could you tell about yourself and your background? 01:20 Why did you join Herantis Pharma? 03:30 What are strengths that you bring to Herantis with you? 05:15 Herantis is “preparing for the next stage of company development” with you as the new CEO. What does this next stage mean for investors? 06:15 I noticed you now have an actual investor relations team. What are your thoughts, why you want to invest more in investor relations right now? What does it tell about your company development? 07:00 Herantis raised more cash, almost 7 million, this spring and now you have around 9 million euros in cash. How long can you operate with these financial resources? 07:30 Has COVID-19 had any impact on your operations? 08:12 Could you give us update where we are at with Lymfactin development? When should we anticipate results on phase II study? 09:04 Update on CDNF? When should we anticipate more news about it? 10:05 You just had successful clinical study with Renishaw Neuro Solutions about drug delivery system, could you comment on that? 10:45 xCNDF update? ​

Herantis Pharma H1'20: Kohti seuraavaa vaihetta (eng)

Pysy ajan tasalla

Viimeisimmät videot